This month has seen some updates for drugs used for HIV pre-exposure prophylaxis (PrEP) and rearranging the way these therapies are displayed on the website.
Following the addition of lenacapavir for PrEP earlier this month, a new entry for emtricitabine/tenofovir-DF for PrEP has been created. These two drugs have been moved into a new HIV drug class (Antiretrovirals for PrEP) along with three PrEP therapies already listed on the website - cabotegravir for PrEP, emtricitabine/tenofovir alafenamide for PrEP and dapivirine.
Interaction summaries between PrEP and other PrEP therapies and between PrEP therapies and antiretrovirals have been simplified and any interactions not already red have been changed to red. These changes have been made as PrEP therapies are not planned to be administered with other PrEP therapies, nor with antiretrovirals.
